Literature DB >> 6772021

Necrotizing enterocolitis: a prospective multicenter investigation.

R W Ryder, J D Shelton, M E Guinan.   

Abstract

Several pre- and post-natal factors possibly important in determining which infants will develop necrotizing enterocolitis (NEC) and which of these infants will die with this disease were prospectively studied in 1976 in 11 infants with radiographic or pathologic evidence of the disease from 12 institutions in the United States and 111 weight-matched, institution-matched control infants. By multivariant discriminant analysis, the authors idenfitied 10 independent significant determinants of NEC and 10 determinants predictive of a fatal outcome among case infants. Determinants of NEC were: Apgar score deterioration; presence of a patent ductus arteriosus; maternal receipt of anesthesia during delivery; infant not treated with parenteral gentamicin before the onset of disease; infant receipt of 10% dextrose solution; treatment of mother with antibiotics during pregnancy; hyperalimentation or gavage feedings; premature rupture of membranes. Important morbid events among cases included red blood cell transfusions, gas in the portal system, premature rupture of membranes, abdominal distension, isolation of Klebsiella organisms from the blood, surgery, prolonged perinatal oxygen requirement, and lower Apgar 2 score. Attempts to modify preventable risk factors may decrease the incidence (2.4 cases per 1000 live births) and case fatality (41%) documented in this study.

Entities:  

Mesh:

Year:  1980        PMID: 6772021     DOI: 10.1093/oxfordjournals.aje.a112960

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  37 in total

1.  Improved closure of patent ductus arteriosus with high doses of ibuprofen.

Authors:  Udo Meißner; Raktima Chakrabarty; Hans-Georg Topf; Wolfgang Rascher; Michael Schroth
Journal:  Pediatr Cardiol       Date:  2012-02-04       Impact factor: 1.655

2.  Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin.

Authors:  R C Coombs; M E Morgan; G M Durbin; I W Booth; A S McNeish
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

3.  Intraoperative measurements of cerebral haemodynamics during ductus arteriosus ligation in preterm infants.

Authors:  E M Saliba; A Chantepie; F Gold; M Marchand; L Pourcelot; J Laugier
Journal:  Eur J Pediatr       Date:  1991-03       Impact factor: 3.183

4.  Echocardiographic assessment of patent ductus arteriosus shunt flow pattern in premature infants.

Authors:  B H Su; T Watanabe; M Shimizu; M Yanagisawa
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-07       Impact factor: 5.747

Review 5.  Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.

Authors:  Palmer G Johnston; Maria Gillam-Krakauer; M Paige Fuller; Jeff Reese
Journal:  Clin Perinatol       Date:  2012-01-13       Impact factor: 3.430

6.  Contribution of oxygen-derived free radicals to experimental necrotizing enterocolitis.

Authors:  D A Clark; D M Fornabaio; H McNeill; K M Mullane; S J Caravella; M J Miller
Journal:  Am J Pathol       Date:  1988-03       Impact factor: 4.307

Review 7.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

8.  Quantitative study of the aerobic and anaerobic faecal flora in neonatal necrotising enterocolitis.

Authors:  C M Westra-Meijer; J E Degener; G Dzoljic-Danilovic; M F Michel; J W Mettau
Journal:  Arch Dis Child       Date:  1983-07       Impact factor: 3.791

9.  Doppler sonographic detection of increased flow velocities in the celiac trunk and superior mesenteric artery in infants with necrotizing enterocolitis.

Authors:  K H Deeg; T Rupprecht; E Schmid
Journal:  Pediatr Radiol       Date:  1993

10.  ADEPT - Abnormal Doppler Enteral Prescription Trial.

Authors:  Alison Leaf; Jon Dorling; Steve Kempley; Kenny McCormick; Paul Mannix; Peter Brocklehurst
Journal:  BMC Pediatr       Date:  2009-10-02       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.